Holen Sie sich die Stockscreener-App
3.35
3.40%
0.11
Schlusskurs vom Vortag:
$3.24
Offen:
$3.24
24-Stunden-Volumen:
833.26K
Relative Volume:
0.91
Marktkapitalisierung:
$139.50M
Einnahmen:
$123.87M
Nettoeinkommen (Verlust:
$62.49M
KGV:
2.0066
EPS:
1.6695
Netto-Cashflow:
$-87.53M
1W Leistung:
-4.01%
1M Leistung:
+9.12%
6M Leistung:
-14.32%
1J Leistung:
-43.41%
1-Tages-Spanne:
$3.10
$3.385
1-Wochen-Bereich:
$3.10
$3.63
52-Wochen-Spanne:
$2.71
$7.34
Agenus Inc Stock (AGEN) Company Profile
Firmenname
Agenus Inc
Sektor
Branche
Telefon
781-674-4410
Adresse
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.35 | 139.50M | 123.87M | 62.49M | -87.53M | 1.6695 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-07-19 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-07-18 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-06-06 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-02-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-09-28 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-04-22 | Eingeleitet | B. Riley FBR | Buy |
| 2016-10-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2016-10-27 | Bestätigt | Maxim Group | Buy |
| 2016-03-11 | Hochstufung | Maxim Group | Hold → Buy |
| 2015-12-16 | Eingeleitet | Jefferies | Buy |
| 2015-10-27 | Herabstufung | Maxim Group | Buy → Hold |
| 2015-07-27 | Bestätigt | MLV & Co | Buy |
| 2015-06-11 | Eingeleitet | Oppenheimer | Outperform |
| 2015-01-12 | Bestätigt | Maxim Group | Buy |
| 2015-01-09 | Bestätigt | MLV & Co | Buy |
| 2015-01-09 | Bestätigt | Maxim Group | Buy |
| 2014-12-19 | Bestätigt | Maxim Group | Buy |
| 2014-05-08 | Bestätigt | Maxim Group | Buy |
| 2014-03-14 | Bestätigt | MLV & Co | Buy |
| 2013-10-08 | Bestätigt | Maxim Group | Buy |
| 2012-01-05 | Eingeleitet | William Blair | Outperform |
| 2011-12-01 | Eingeleitet | Global Hunter Securities | Buy |
Alle ansehen
Agenus Inc Aktie (AGEN) Neueste Nachrichten
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026 - AOL.com
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC - AOL.com
Form 4 Agenus Inc For: 7 July By Investing.com - Investing.com Nigeria
Agenus (NASDAQ: AGEN) director Harrison awarded 8,547 shares as board compensation - Stock Titan
Director Wright of Agenus (NASDAQ: AGEN) granted deferred stock units - Stock Titan
Agenus Inc. Amends Notes and Issues New Warrants in 2026 Definitive Agreement – Key Details and Terms - Minichart
Agenus Extends $5.09M Notes to 2027, Lengthens Warrants to 2031 and Issues New D Warrants - TradingView
Agenus (NASDAQ: AGEN) extends note maturity and long-dated warrants - Stock Titan
Agenus Reports Landmark 3-Year OS Data for BOT+BAL in Refractory MSS mCRC at ESMO GI - Oncodaily
Agenus BOT+BAL Shows 33% Three-Year Survival in Immunotherapy-Resistant Colorectal Cancer - BioPharm International
BOT+BAL Continues to Show Durable Clinical Benefit in MSS mCRC – Agenus - Oncodaily
Agenus (AGEN) Reports Promising Data on BOT/BAL Therapy for Colo - GuruFocus
Agenus reports 3-year survival data in colorectal cancer study - grafa.com
Agenus Achieves 33% Three-Year Survival in Colorectal Cancer - AllSci
Agenus reports 3-year survival data for colorectal cancer therapy - Investing.com
Agenus (AGEN) Reports Promising Long-Term Survival Data for BOT+ - GuruFocus
Agenus reports 3-year survival data for colorectal cancer therapy By Investing.com - Investing.com Nigeria
Form 4 Agenus Inc For: 30 June By Investing.com - Investing.com Australia
Agenus (AGEN) director Armen takes June 2026 salary in 5,364 company shares - Stock Titan
Agenus Inc.(NasdaqCM: AGEN) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 2000 Index - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 2500 Growth Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 2000 Value Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 3000E Value Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 2000 Growth Benchmark - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 3000E Index - marketscreener.com
Agenus Inc.(NasdaqCM: AGEN) added to Russell 3000E Growth Benchmark - marketscreener.com
Durable Outcomes in MSS Metastatic Colorectal Cancer Without Active Liver MetastasesAgenus - Oncodaily
Price to sales forward of Agenus Inc. – NASDAQ:AGEN - TradingView
Enterprise value to EBITDA forward of Agenus Inc. – NASDAQ:AGEN - TradingView
Enterprise value to revenue forward of Agenus Inc. – NASDAQ:AGEN - TradingView
Price to book forward of Agenus Inc. – NASDAQ:AGEN - TradingView
Enterprise value to EBIT forward of Agenus Inc. – NASDAQ:AGEN - TradingView
Agenus Inc. Actuals & Estimates (BX:AGEN) - TradingView
Agenus Inc. Actuals & Estimates (NASDAQ:AGEN) - TradingView
AGEN Forecast — Price Target — Prediction for 2027 - TradingView
Agenus Inc. Actuals & Estimates (TRADEGATE:AJ8) - TradingView
Agenus to present 3-year cancer trial data at ESMO conference - Investing.com South Africa
Agenus Challenges 'Untreatable' Status of a Common Colorectal Cancer - BriefGlance
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026 - BioSpace
Agenus (AGEN) Set to Present Promising Survival Data at ESMO 202 - GuruFocus
Agenus Announces Three-Year Survival Data From Phase 1B Bot+Bal Study In Mss Metastatic Colorectal Cancer To Be Presented At Esmo Gi 2026 - TradingView
Agenus Shareholders Approve Governance, Compensation and Auditors - The Globe and Mail
Speed and Rigor Are Not in Conflict – Garo Armen - Oncodaily
Form 8K Agenus Inc For: 23 June By Investing.com - Investing.com Nigeria
Agenus Inc. Files Form 8-K with SEC: Corporate Details, Stock Information & Key Disclosures (June 16, 2026) 25 - Minichart
Form 8K Agenus Inc For: 23 June - Investing.com UK
Agenus (NASDAQ: AGEN) investors approve equity plan changes and KPMG - Stock Titan
Agenus Inc (AGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Agenus Inc (AGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Agenus Inc (AGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Finanzdaten der Agenus Inc-Aktie (AGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):